AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$ROIV

Venker Eric sold $7.3M of ROIV

Venker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $36.62 ($7.32M total) on 2026-09-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Venker Eric
Published Oct 2, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
high confidence
Mentioned
$ROIV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

Insider sell of $7.3M may trigger short‑term price weakness, but the size is modest relative to market cap.

02

Market read

Primary relevance is the insider sale; limited broader market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 6/10Timing: post‑market on filing day

Background

SEC Form 4 filing discloses insider transactions required by regulators.

Company-level read

Ticker impact

$ROIVBearishHigh confidence
Context

President & Immunovant CEO Eric Venker sold 200,000 shares for $7.3M via a Form 4 filing on 2026-09-30.

Expected impact

likely downward pressure as investors price in the insider sell

Evidence & confidence

A senior executive sold a sizable stake ($7.3M) under a 10b5‑1 plan, which often precedes negative sentiment.

Market effects

Sector

Minimal impact on biotech sector; isolated insider transaction.

Regional

U.S. market only; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged 10b5‑1 plan and not reflect negative outlook.

Key entities

  • company
    Roivant Sciences Ltd.

    Biopharma company listed on Nasdaq under ticker ROIV.

  • person
    Eric Venker

    President & Immunovant CEO, reporting insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min